BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$304.15 USD
+8.63 (2.92%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $304.14 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIO 304.15 +8.63(2.92%)
Will BIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIO
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
Phibro (PAHC) Down 3.3% Since Last Earnings Report: Can It Rebound?
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Other News for BIO
Ariel Investments Q1 2024 Small Cap Value Strategy Letter
Ariel Investments Mid Cap Value Q1 2024 Commentary
RBC Capital Remains a Buy on Bio-Rad Laboratories (BIO)
Biome Australia Bolsters Finances, Plans Strategic Growth
Biome Australia Expands ASX Quotation